Postgraduate Institute of Medical Education and Research is a public medical university in Chandigarh, India. It is an 'Institute of National Importance'. It has educational, medical research, and training facilities for its students including all specialties, super specialties and sub specialties.

During the past decade, PGIMER conducted 177 clinical trials. In the 10-year time frame, 177 clinical trials started and 17 clinical trials were completed, i.e. on average, 9.6% percent of trials that started reached the finish line to date. In the past 5 years, 89 clinical trials started and 11 clinical trials were completed. i.e. 12.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "PGIMER" #1 sponsor was "Postgraduate Institute of Medical Education and Research" with 134 trials, followed by "Janssen Research & Development, LLC" with 8 trials sponsored, "Cadila Pharnmaceuticals" with 7 trials sponsored, "Eli Lilly and Company" with 7 trials sponsored and "Abbott Medical Devices" with 7 trials sponsored. Other sponsors include 71 different institutions and companies that sponsored additional 53 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "PGIMER" #1 collaborator was "Postgraduate Institute of Medical Education and Research" with 7 trials as a collaborator, "Council of Scientific and Industrial Research, India" with 4 trials as a collaborator, "Indian Council of Medical Research" with 4 trials as a collaborator, "Postgraduate Institute of Medical Education and Research, Chandigarh" with 4 trials as a collaborator and "All India Institute of Medical Sciences, New Delhi" with 3 trials as a collaborator. Other collaborators include 118 different institutions and companies that were collaborators in the rest 111 trials.

According to Clinical.Site data, the most researched conditions in "PGIMER" are "Cirrhosis, Liver" (9 trials), "Acute-On-Chronic Liver Failure" (6 trials), "Type 2 Diabetes Mellitus" (6 trials), "COVID-19" (5 trials) and "Covid19" (4 trials). Many other conditions were trialed in "PGIMER" in a lesser frequency.

Most popular intervention types in "PGIMER" are "Drug" (136 trials), "Other" (45 trials), "Device" (18 trials), "Procedure" (17 trials) and "Biological" (12 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (29 trials), "Growth Hormone" (4 trials), "Bortezomib" (3 trials), "Dexamethasone" (3 trials) and "Direct Acting Antivirals" (3 trials). Other intervention names were less common.

The vast majority of trials in "PGIMER" are 227 trials for "All" genders, 6 trials for "Male" genders and 4 trials for "Female" genders.

Currently, there are NaN active trials in "PGIMER". 3 are not yet recruiting, 48 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 111 completed trials in PGIMER, undefined suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in PGIMER, 6 "Phase 1" clinical trials were conducted, 32 "Phase 2" clinical trials and 72 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 33 trials, and there were also 65 trials that are defined as “Not Applicable".

PGIMER has several departments that took part in Clinical trials: "Dr Budhi Singh Yadav" - 5 trials, "Dept. of Hepatology, PGIMER" - 3 trials